行情

CERC

CERC

Cerecor
NASDAQ

实时行情|Nasdaq Last Sale

3.470
+0.030
+0.87%
盘后: 3.470 0 0.00% 16:29 10/17 EDT
开盘
3.480
昨收
3.440
最高
3.540
最低
3.420
成交量
3.25万
成交额
--
52周最高
7.65
52周最低
2.710
市值
1.49亿
市盈率(TTM)
-2.8614
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CERC 新闻

  • 美联储Evans建议探寻最大就业的真实水平
  • 新浪美股.1小时前
  • 首相约翰逊面临"超级星期六" "脱欧"迎来摊牌时刻
  • 新浪美股.2小时前
  • 沙特阿美据称推迟IPO 拟理清近期季度业绩后再上市
  • 新浪美股.2小时前
  • 美国电子烟巨头Juul暂停销售大部分的调味电子烟
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
+0.83%
制药与医学研究
+0.62%

热门股票

名称
价格
涨跌幅

CERC 简况

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.
展开

Webull提供Cerecor Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。